Orexigen, Takeda deal

Orexigen and Takeda terminated the U.S. portion of a 2010 deal granting Takeda exclusive rights to commercialize obesity drug Contrave naltrexone/bupropion in North America. Orexigen regained Canadian and Mexican rights last year.

The U.S. transaction is expected to close in late March followed by a 180-day transition period. During the transition, Takeda will continue to commercialize Contrave in the U.S., during which Orexigen will be eligible for royalties. Both companies will share clinical development costs during the transition. ...